PLK1 inhibition-based combination therapies for cancer management

Polo-like kinase I (PLK1), a cell cycle regulating kinase, has been shown to have oncogenic function in several cancers. Although PLK1 inhibitors, such as BI2536, BI6727 (volasertib) and NMS-1286937 (onvansertib) are generally well-tolerated with a favorable pharmacokinetic profile, clinical success...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Shengqin, Chhabra, Gagan, Singh, Chandra K., Ndiaye, Mary A., Ahmad, Nihal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728518/
https://www.ncbi.nlm.nih.gov/pubmed/34973570
http://dx.doi.org/10.1016/j.tranon.2021.101332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728518/
https://www.ncbi.nlm.nih.gov/pubmed/34973570
http://dx.doi.org/10.1016/j.tranon.2021.101332

Ejemplares similares